GlassScriptPhysician profile
Tamoya Thomas
NPI 1447956016
$1,325.87
in general payments reported to CMS, 2019-2025
13 companies · $24.89 in 2025
The $24.89 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $282 · 2024: $1,019 · 2025: $24.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,325.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $216.42 | 2023-2024 | Jornay Pm |
| Abbvie INC. | $214.93 | 2023-2024 | |
| Lundbeck LLC | $204.08 | 2023-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $190.91 | 2023-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Bausch Health US, LLC | $153.03 | 2024 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $108.91 | 2023-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.49 | 2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $42.87 | 2023-2024 | Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $40.27 | 2024 | Invega Sustenna |
| Alkermes, INC. | $30.93 | 2024 | Aristada, Lybalvi |
| Collegium Pharmaceutical, INC. | $24.89 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $19.37 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $16.77 | 2024 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamoya Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.